M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68% Market Closed
Market Cap: 2.4B SAR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 94.41 SAR. Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
94.41 SAR
Overvaluation 22%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

6.2
P/S
P/S
Price to Sales
6.2
vs History
6
vs Industry
31
Median 3Y
5.3
Median 5Y
5.3
Industry
2.4
Forward
5.3
More Details
30.4
P/E
P/E
Price to Earnings
30.4
vs History
18
vs Industry
20
Median 3Y
28.9
Median 5Y
28.9
Industry
20.6
Forward
23.3
More Details
68.7
P/OCF
P/OCF
Price to OCF
68.7
vs History
0
vs Industry
13
Median 3Y
32.4
Median 5Y
32.4
Industry
15.5
More Details
168.1
P/FCFE
P/FCFE
Price to FCFE
168.1
vs History
0
vs Industry
7
Median 3Y
94.7
Median 5Y
94.7
Industry
23
More Details
6.6
P/B
P/B
Price to Book Value
6.6
vs History
62
vs Industry
9
Median 3Y
7.4
Median 5Y
7.4
Industry
1.9
More Details
6.3
EV/S
EV/S
Enterprise Value to Sales
6.3
vs History
6
vs Industry
29
Median 3Y
5.4
Median 5Y
5.4
Industry
2.5
Forward
5.4
More Details
10.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.1
vs History
6
vs Industry
31
Median 3Y
8.9
Median 5Y
8.9
Industry
4.9
More Details
23.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.1
vs History
6
vs Industry
21
Median 3Y
21.5
Median 5Y
21.5
Industry
12.6
Forward
19.3
More Details
27.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.1
vs History
6
vs Industry
21
Median 3Y
24.4
Median 5Y
24.4
Industry
15.7
Forward
21
More Details
69.8
EV/OCF
EV/OCF
Enterprise Value to OCF
69.8
vs History
0
vs Industry
13
Median 3Y
33.1
Median 5Y
33.1
Industry
14
More Details
171.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
171.8
vs History
0
vs Industry
8
Median 3Y
60.8
Median 5Y
60.8
Industry
17.7
More Details
5.2
EV/IC
EV/IC
Enterprise Value to IC
5.2
vs History
62
vs Industry
14
Median 3Y
5.7
Median 5Y
5.7
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Middle East Pharmaceutical Industries Company SJSC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SA
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
2.4B SAR 6.2 30.4 23.1 27.1
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
SA
M
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Average P/E: 26.7
30.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.